SOMOS

What SOMOS does

SOMOS is a health technology company founded in 2018 and headquartered in San Francisco, operating a genetic research platform that aggregates genetic data from underrepresented Latino populations. The company is building what it describes as the largest decentralized biobank for these communities, with the stated objective of enabling the development of tailored medicines and offering ancestry testing services (global and Latin American). The platform is co-founded by Federico W. von Son (CEO) and Christian M Rodriguez (CTO/Co-founder), and operates with a small team of 1-10 employees.

The company's go-to-market is community-led, relying on a crowdfunding campaign (closed October 10, 2022) and direct outreach to Latino populations to fund biobank expansion and drive participation in genetic data collection. Its stated revenue model is freemium, and its customer segmentation is vertical — focused on a single primary segment (Latino populations) participating in genetic research and ancestry testing. To date, the company has disclosed five funding events totaling roughly $560,000 from 2017 to 2022, with investors including the Mexican government's Innovation Fund (CONACYT) and LTX Fest.

Material caveats temper the operating picture: total disclosed funding is modest, funding cadence has declined since the 2018 round, no enterprise customers, partnerships, patents, or hires are disclosed, and the company website (somosancestria.com) currently resolves to an unrelated restaurant menu (True Seasons Organic Kitchen). These signals together suggest the company may be in a very early stage, paused, or operationally constrained, and investors should treat the platform's commercial status as unverified.

Name

SOMOS

Website

https://somosancestria.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

SOMOS is a health technology company operating a genetic research platform and decentralized biobank that aggregates genetic data from Latino populations to offer ancestry testing and support the development of tailored medicines for underrepresented communities.

Ownership category

akta.pro rank

Product category

Consumer Genetic Testing & Genomics

NAICS

Medical and Diagnostic Laboratories (6215), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD)

akta.pro secondary industries

Genetic & Prenatal Testing Laboratories (HLAFAMAH), Bioinformatics, Multi-Omics Data Analysis & Interpretation Services (HLAGANAI)

Keywords

• Genetic testing services
• Ancestry DNA testing
• Decentralized biobank
• Population genetics research
• Precision medicine data

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Markets served

GTM type

B2C

Offering type

Software

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Crowdfunding Campaign: The company raised funds through a crowdfunding campaign on October 10, 2022, to expand its genetic research platform focused on Latino populations.

Go-to-market motion1 record

Marketing channels1 record

Core offering

SOMOS operates a genetic research platform that offers global ancestry and Latin American ancestry tests to consumers while building a decentralized biobank of genetic data from underrepresented Latino populations. The platform aggregates genetic data to support medical research and the development of tailored medicines specifically for Latino communities.

Product overview

SOMOS is a health technology company operating as a single unified product offering — a genetic research platform. The company is building what it describes as the largest decentralized biobank, utilizing genetic data collected from underrepresented populations (specifically Latino communities) to support the development of tailored medicines. The platform appears to be in an expansion phase, as evidenced by its October 2022 crowdfunding campaign.

Differentiator

Problem solved

Functional benefit

Products and services

• Genetic Research Platform A health technology platform that collects and analyzes genetic data from underrepresented Latino populations for ancestry insights and to support the development of tailored medicines through medical research.
• Global & Latin American Ancestry Tests Consumer-facing genetic ancestry tests offering global ancestry and Latin American ancestry insights, provided to individual Latino consumers through the SOMOS platform.
• Decentralized Biobank A decentralized biobank that aggregates genetic data contributed by community participants across Latino populations, intended to be the largest such resource for underrepresented groups and to enable tailored medicine research.

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators1 record

Recent moves5 records

Expansion highlights3 records

Direct peers

• 23andMe: Leading direct-to-consumer genetic testing company offering ancestry and health reports. Direct competitor to SOMOS with established scale, though less specialized on Latino populations.
• Ancestry (AncestryDNA): Major consumer ancestry testing service with the largest DNA database globally. Competes directly with SOMOS in ancestry and has begun offering health-related genetic reports.
• MyHeritage: Genetic testing and genealogy platform with significant overlap in ancestry-focused DNA testing, serving multicultural consumer bases including Hispanic communities.
• African Ancestry: Genetic testing company focused on African diaspora ancestry. Closest analog to SOMOS's niche-population specialization strategy, demonstrating the underserved-market thesis in action.
• Nebula Genomics: Decentralized genomic data platform using blockchain-based privacy controls. Conceptually aligned with SOMOS's decentralized biobank model and serves consumers seeking whole-genome sequencing.

Broad incumbents

• Helix: Genomic testing platform partnering with health systems and developers. Broader incumbent with overlapping infrastructure for population-scale genetic data, though with a B2B-focused model rather than community-led.
• Color Genomics: Population genomics company offering genetic testing at scale, including for employers and health systems. Broader incumbent with overlapping capability in scaling genetic data collection for diverse populations.
• GeneDx: Clinical genomics company providing genetic testing and interpretation services. Comparable in lab infrastructure and clinical genetic testing operations, though focused on rare disease diagnostics rather than ancestry.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights5 records

Customer concentration

• Xx.com/somosancestria
• Facebookfacebook.com/SomosAncestria
• LinkedInlinkedin.com/company/somos-ancestria

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SOMOS